Robert Hazlett
Stock Analyst at BTIG
(0.55)
# 3,978
Out of 4,918 analysts
23
Total ratings
33.33%
Success rate
-23.82%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $6.75 | +255.56% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $22.96 | +161.32% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $0.53 | +2,549.51% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $1,200 → $1,000 | $6.58 | +15,097.57% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $103.02 | -4.87% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $6.08 | +886.84% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $4.34 | +1,351.61% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $6.81 | +325.84% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $1.20 | +2,166,566.67% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $3.72 | +61.29% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $13.21 | +36.26% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $6.75
Upside: +255.56%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $22.96
Upside: +161.32%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $0.53
Upside: +2,549.51%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $1,200 → $1,000
Current: $6.58
Upside: +15,097.57%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $103.02
Upside: -4.87%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $6.08
Upside: +886.84%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $4.34
Upside: +1,351.61%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $6.81
Upside: +325.84%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $1.20
Upside: +2,166,566.67%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $3.72
Upside: +61.29%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $13.21
Upside: +36.26%